New form of SMA treatment Evrysdi may give patients 'freedom'

Check Out Cure SMA’s 2024 Annual State of SMA Report

Check Out Cure SMA’s 2024 Annual State of SMA Report Cure SMA is pleased to announce the launch of our next State of SMA report, showcasing data through 2024. The annual data report highlights data from Cure SMA’s three databases: a patient-reported database with data from over 11,000 impacted individuals worldwide that also incorporates longitudinal data from our annual Community Update Survey; the SMA Clinical Data Registry (CDR) that contains…

New form of SMA treatment Evrysdi may give patients 'freedom'

A tablet formulation of Evrysdi (risdiplam) for spinal muscular atrophy (SMA) recently approved in the U.S. is designed to give patients a new option, a Genentech official said. “Evrysdi is the only oral, non-invasive disease-modifying SMA treatment, and the new tablet formulation may provide greater freedom and independence for people with SMA, thanks to simplified dose administration,” said Gregory Rippon, MD, vice president and chief medical …